Publikationen Prof. Dr. med. Martin Burchardt

Transcription

Publikationen
Prof. Dr. med. Martin Burchardt
PUBLIKATIONEN
(Kumulativer Impact Factor aller Original- und Übersichtsarbeiten: 208,41)
Originalarbeiten
1. Burchardt M, Burchardt T, Chen MW, Shabsigh A, de la Taille A, Buttyan R, Shabsigh R.
Expression of messenger RNA splice variants for Vascular Endothelial Growth Factor in the adult
rat and human penis. Biol Reprod 1999;60(2):398-404 (IF 3,498)
2. Burchardt M, Burchardt T, Chen MW, Buttyan R, de la Taille A, Shabsigh A, Shabsigh R.
Expression of VEGF splice variants 144/145 and 205 in adult male tissues. IUBMB Life 1999;
48(4):405-8 (IF 2,316)
3. Burchardt M, Burchardt T, Chen MW, Hayek OR, Knight C, Shabsigh A, de la Taille A, Buttyan
R. Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early
effects of castration. Prostate 2000;43(3):184-94 (IF 3,724)
4. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A, de la Taille A, Hayek O,
Shabsigh R. Hypertension is associated with severe erectile dysfunction. J Urol
2000;164(4):1188-91 (IF 3,956)
5. Burchardt M, Burchardt T, Shabsigh A, Ghafar M, Chen MW, Anastasiadis A, de la Taille A,
Buttyan R. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP
prostate cancer cells. Prostate 2001;48(4):225-230 (IF 3,724)
6. Burchardt M, Burchardt T, Anastasiadis AG, Kiss AJ, Shabsigh A, de la Taille A, Pawar RV, Baer
L, Shabsigh R. Erectile dysfunction is a marker for cardiovascular complications and
psychological functioning in men with hypertension. Int J Impot Res 2001;13:276-81 (IF 2,353)
7. Burchardt M, Burchardt T, Kiss AJ, Baer L, Pawar RV, de la Taille A, Shabsigh A, Shabsigh R.
Sexual dysfunction is overlooked in female patients with hypertension. J Sex Marital Ther
2002;28:17-26 (IF 1,853)
8. Burchardt M, Voegeli TA, Sulser T, Fornara P, Rassweiler J. Results of a survey concerning
laparoscopic surgery among urologists in Germany and Switzerland. Eur Urol 2002;42(5):441-6
(IF 5,634)
9. Burchardt M, Burchardt T, Anastasiadis A, Buttyan R, de la Taille A, Shabsigh A, Frank J,
Shabsigh R. Application of angiogenic factors for therapy of erectile dysfunction: Protein and DNA
transfer of VEGF 165 into the rat penis. Urology 2005;66(3):665-70 (IF 2,130)
10. Burchardt M, Engers R, Mueller M, Burchardt T, Ackermann R, Gabbert HE, Epstein J I, Rubin
MA. Interobserver reproducibility of Gleason grading: Evaluation using prostate cancer tissue
microarrays. J Cancer Res Clin Oncol 2008, Epub ahead of print. (IF 2,469)
11. Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de la Taille A, Ackermann R,
Burchardt M. The androgen receptor in hormone-refractory prostate cancer: Relevance of
different mechanisms of androgen receptor signaling. Int J Oncol 2003;23(4):1095-102 (IF 2,556)
12. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function
diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene
2004;23(20):3541-9 (IF 6,582)
13. Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/beta-catenin pathway
activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines.
Int J Oncol 2005;26(4):1033-40 (IF 2,556)
14. Herrmann TR, Rabenalt R, Stolzenburg JU, Liatsikos EN, Imkamp F, Tezval H, Gross AJ, Jonas
U, Burchardt M. Oncological and functional results of open, robot-assisted and laparoscopic
radical prostatectomy: does surgical approach and surgical experience matter? World J Urol
2007;25(2):149-60 (IF 2,217)
15. Herrmann TRW, Bach T, Imkamp F, Tezval H, Klot C, Jonas U, Gross AJ, Burchardt M.
FlexGuardTM – a new laser insertion sheath. Functional aspects in ureterorenoscopy (URS).
World J Urol 2007; 25(3):269-73 (IF 2,217)
16. Prowald W, Cronauer MV, von Klot C, Eilers T, Rinnab L, Herrmann T, Spindler KD, Montenarh
M, Jonas U, Burchardt M. Modulation of beta-catenin-mediated TCF-signalling in prostate cancer
cell lines by wild-type and mutant p53. Prostate 2007;67(16):1751-60 (IF 3,724)
17. Imkamp F, Herrmann TRW, Jonas U, Rassweiler J, Stolzenburg J, Rabenalt R, Sulser T,
Burchardt M. Laparoscopy in Urology: Changing acceptance among urologists. Eur Urol 2008,
epub ahead of print, 7. Oct. 2008 (IF 5,634)
1
Publikationen
18. Klein LT, Miller MI, Buttyan R, Raffo AJ, Burchardt M, Devries G, Cao YC, Olsson CA, Shabsigh
R. Apoptosis in the rat penis after penile denervation. J Urol 1997;158(2):626-30 (IF 3,956)
19. Burchardt T, Burchardt M, Chen MW, Shabsigh A, de la Taille A, Omar Hayek, Buttyan R.
Transdifferentation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
J Urol 1999;162(5):1800-5 (IF 3,956)
20. De la Taille A, Chen MW, Burchardt M, Chopin DK, Buttyan R. Apoptotic Conversion: Evidence
for exchange of genetic information between prostate cancer cells mediated by apoptosis. Cancer
Res 1999;59(21):5461-3 (IF 7,656)
21. De la Taille A, Hayek OR, Buttyan R, Bagiella B, Burchardt M, Katz AE. Effects of a
phytotherapeutic agent, PC SPES, on prostate cancer: a preliminary investigation on human cell
lines and patients. BJU Int 1999;84(7):845-50 (IF 2,635)
22. De la Taille A, Olsson CA, Buttyan R, Benson M, Bagiella E, Cao Y, Burchardt M, Chopin DK,
Katz AE. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic
specific antigen: Long term follow-up confirms the utility of this assay in identifiying patients more
likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int J Cancer
1999;84:360-64 (IF 4,693)
23. Shabsigh A, Tanji N, D'Agati V, Burchardt T, Burchardt M, Hayek O, Shabsigh R, Buttyan R. The
vascular anatomy of the rat ventral prostate. Anat Rec 1999;256(4):403-11 (IF 1,973)
24. Shabsigh R, Shabsigh A, Burchardt M, Burchardt T, Karden J. Erectile dysfunction and
depression: a dynamic association. Sexual Dysfunction in Medicine 1999;1(2):42-45 (IF 1,273)
25. Shabsigh A, Buttyan R, Burchardt T, Burchardt M, Hayek O, D’Agati V, Olsson CA, Shabsigh R.
The microvascular architecture of the rat vagina, revealed by image analysis of vascular corrosion
casts. Int J Impot Res 1999;Suppl 1:23-30 (IF 2,353)
26. Shabsigh A, Tanji N, D'Agati V, Burchardt M, Hayek O, Rubin M, Goluboff ET, Heitjan D, Kiss A,
Buttyan R. Early effects of castration on the vascular system of the rat ventral prostate gland.
Endocrinology 1999;140(4):1920-6 (IF 5,236)
27. Hayek O, Shabsigh A, Kaplan SA, Kiss AJ, Chen MW, Burchardt T, Burchardt M, Olsson CA,
Buttyan R. Castration induces acute vasoconstriction of blood vessel in the rat prostate
concomitant with a rapid reduction of blood flow. J Urol 1999;162(4):1527-31 (IF 3,956)
28. Shabsigh A, Hayek OR, Weiner D, Saidi J, Kaplan SA, Kiss A, Burchardt M, Buttyan R, Levin
RM. Acute increase in blood flow to the rat bladder subsequent to partial bladder outlet
obstruction. Neurourol Urodyn 2000;19(2):195-208;discussion 206-8 (IF 2,436)
29. De la Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA, Katz AE.
Cryoablation for clinically localized prostate cancer using an argon-based system: complication
rates and biochemical recurrence. BJU Int 2000;85(3):281-6 (IF 2,635)
30. Burchardt T, Burchardt M, Karden J, Buttyan R, Shabsigh A, de la Taille A, Ng PY, Anastasiadis
AG, Shabsigh R. Reduction of endothelial and smooth muscle density in the corpora cavernosa of
the streptozotocin induced diabetic rat. J Urol 2000;164(5):1807-11 (IF 3,956)
31. De la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Katz AE.
Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in prostate cancer. J Urol
2000; 164(4):1229-34 (IF 3,956)
32. De la Taille A, Rubin MA, Buttyan R, Olsson CA, Bagiella E, Burchardt M, Wellisch OM, Katz AE.
Is microvascular invasion on radical prostatectomy specimens a useful predictor of PSA
recurrence for prostate cancer patients? Eur Urol 2000;38(1):79-84 (IF 5,634)
33. De la Taille A, Cao Y, Sawczuk IS, Nozemu T, d’Agati V, McKiernan JM, Bagiella E, Buttyan R,
Burchardt M, Olsson CA, Bander N, Katz AE. Detection of prostate specific membrane antigen
expressing cells in blood from renal cancer patients: A potential biomarker of vascular invasion.
Cancer Detect Prev 2000;24(6):579-88 (IF 1,622)
34. De la Taille A, Katz A, Cao Y, McKiernan J, Buttyan R, Burchardt M, Burchardt T, Hayek O,
Olsson CA, Chopin DK, Sawczuk IS: Blood-based RT-PCR assays of MN/CA9 or PSMA: Clinical
application in renal cancer patients. Urology 2000;56(3):393-98 (IF 2,130)
35. Anastasiadis AG, Wilson SK, Burchardt M, Shabsigh R. Long term outcomes of inflatable
implants: Reliability, patient satisfaction and complication management. Curr Opin Urol
2001;11:619-23 (IF 2,684)
2
Publikationen
36. Shabsigh A, Ghafar MA, de la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan R.
Biomarker analysis demonstrates a hypoxic environment in the castrated ventral prostate gland. J
Cell Biochem 2001;81(3):437-44 (IF 3,409)
37. Voegeli TA, Burchardt M, Sulser T, Fornara P, Rassweiler J. Results of a survey concerning
laparoscopic surgery among german urologists. Urologe A 2002;41(2):120-22 (IF 0,404)
38. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Burchardt M, Seifert HH,
Visakorpi T. Genome-Wide DNA hypomethylation is associated with alterations on chromosome 8
in prostate carcinoma. Gene Chromosome Canc 2002;35:58-65 (IF 3,900)
39. Chen MW, Vacherot F, de la Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, Burchardt
M, Chopin DK, Buttyan R. The emergence of protocadherin-PC expression during the acquisition
of apoptosis-resistance by prostate cancer cells. Oncogene 2002;21(51):7861-71 (IF 6,582)
40. Anastasiadis AG, Ghafar MA, Salomon L, Vacherot F, Benedit P, Chen MW, Shabsigh A,
Burchardt M, Chopin DK, Shabsigh R, Buttyan R. Human hormone-refractory prostate cancers
can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor1alpha (HIF-1alpha). J Cancer Res Clin Oncol 2002;128(7):358-62 (IF 2,469)
41. Anastasiadis AG, Stisser BC, Ghafar MA, Burchardt M, Buttyan R. Tumor hypoxia and the
progression of prostate cancer. Current Urology Reports 2002;3:222-8 (IF 1,731)
42. Ghafar MA, Anastasiadis AG, Chen MW, Burchardt M, Olsson LE, Xie H, Benson MC, Buttyan
R. Acute Hypoxia increases the agressive characteristics and survival properties of prostate
cancer cells. Prostate 2003;54:58-67 (IF 3,724)
43. Anastasiadis AG, Davis AR, Sawczuk IS, Fleming M, Perelman MA, Burchardt M, Shabsigh R.
Quality of life aspects in kidney cancer patients: data from a national registry. Support Care
Cancer 2003;11:700-6
44. De la Taille A, Rubin MA, Vacherot F, Chen MW, Vacherot F, de Medina SGD, Burchardt M,
Buttyan R, Chopin D. ß-Catenin-related anomalies in apoptosis resistant and hormone-refractory
prostate cancer cells. Clin Cancer Res 2003;9(5):1801-7 (IF 6,177)
45. Anastasiadis AG, Calvo-Sanchez D, Franke KH, Ebert T, Heydthausen M, Schulz WA, Burchardt
M, Gerharz CD. P27KIP1-expression in human renal cell cancers:implication for clinical outcome.
Anticancer Res 2003;23(1A):217-21 (IF 1,479)
46. Anastasiadis AG, Benson MC, Rosenwasser MP, Salomon L, El-Rashidy H, Ghafar MA,
McKiernan JM, Burchardt M, Shabsigh R. Cavernous nerve graft reconstruction during radical
prostatectomy or radical cystectomy: safe and technically feasible. Prostate Cancer 2003;6(1):5660 (IF 1,810)
47. Stolzenburg JU, Rabenalt R, Do M, Truss MC, Burchardt M, Herrmann TRW, Schwalenberg T,
Kallidonis P, Liatsikos EN. Endoscopic extraperitoneal radical prostatectomy: The University of
Leipzig experience of 1,300 cases. World J Urol 2007;25(1):45-51 (IF 2,217)
48. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV, Burchardt M, Kleinert
H, Wiedenmann J, Sies H, Ackermann R, Kroncke KD. Nitric oxide-mediated inhibition of
androgen receptor activity: possible implications for prostate cancer progression. Oncogene
2007;26(13):1875-84 (IF 6,582)
49. Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ. RevoLix vaporesection of the
prostate: initial results of 54 patients with a 1-year follow-up. World J Urol 2007;25(3):257-62 (IF
2,7)
50. Liatsikos E, Mühlstädt S, Kallidonis P, Rabenalt R, Do M, Burchardt M, Herrmann TR,
Stolzenburg JU. Performance and functional outcome of endoscopic extraperitoneal radical
prostatectomy in relation to obesity: an assessment of 500 patients. BJU Int 2008. Epub ahead of
print. (IF 2,635)
51. Ganzer R, Rabenalt R, Truss MC, Papadoukakis S, Do M, Blana A, Straub M, Denzinger S,
Wieland WF, Burchardt M, Herrmann T, Stolzenburg JU. Evaluation of complications in
endoscopic extraperitoneal radical prostatectomy in a modular training programme: a multicenter
experience. World J Urol 2008; Epub ahead of print. (IF 2,7)
52. Bach T, Herrmann TR, Ganzer R, Blana A, Burchardt M, Gross AJ. Thulium:YAG vaporesection
of the prostate. First results. Urologe A. 2009. 48(5):529-34.
53. Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, Gross AJ. Thulium laser
enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support.
Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol
2010. 28(1):45-51 (IF 2,7).
3
Publikationen
Übersichtsarbeiten
54. Burchardt M, Burchardt T, Shabsigh A, de la Taille A, Sawczuk I. Current concepts in biomarker
technology for bladder cancers. Clin Chem 2000;46(5):595-605 (IF 5,454)
55. Sawczuk IS, Burchardt T, Shabsigh A, de la Taille A, Burchardt M. Bladder cancer markers.
Current availability and the future standard of care. MLO Med Lab Obs 2000;32(3):30-3,36,38
passim; quiz 42-4
56. Herrmann TR, Gross AJ, Schultheiss D, Kaufmann PM, Jonas U, Burchardt M. Transurethral
microwave thermotherapy for the treatment of BPH: still a challenger? World J Urol
2006;24(4):389-96 (2,217)
57. Tezval H, Tezval M, von Klot C, Herrmann TR, Dresing K, Jonas U, Burchardt M. Urinary tract
injuries in patients with multiple trauma. World J Urol 2007;25(2):177-84 (IF 2,217)
58. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human
prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008; Epub
ahead of print. (IF 2,217)
59. De la Taille A, Buttyan R, Katz AE, McKiernan J, Burchardt M, Burchardt T, Chopin DK.
Biomarkers of renal cell carcinoma. Past and future considerations. Urol Oncol 2000;5 (IF 2,089)
60. Anastasiadis AG, Ghafar MA, Burchardt M, Shabsigh R. Economic aspects of medical erectile
dysfunction therapies. Expert Opin Pharmaco 2002;3(3):257-63 (IF 1,733)
61. Anastasiadis AG, Salomon L, Ghafar MA, Burchardt M. Female Sexual Dysfunction: State of the
art. Current Urology Reports 2002;3:484-91 (IF 1,731)
62. Anastasiadis AG, Davis AR, Ghafar MA, Burchardt M, Shabsigh R. Epidemiology and definitions
of female sexual disorders. World J Urol 2002;20:74-78 (IF 2,217)
63. Anastasiadis AG, Davis AR, Salomon L, Burchardt M, Shabsigh R. Hormonal factors in female
sexual dysfunction. Curr Opin Urol 2002;12(6):503-7 (IF 2,684)
64. Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Hum Reprod
2003;9(8):437-48 (IF 2,760)
65. Grimm MO, Burchardt M, Schulz WA. Perspektiven der molekularen Diagnostik dargestellt am
Harnblasencarcinom. Urologe A 2003;42(5):650-9 (IF 0,404)
66. Cronauer MV, Schulz WA, Seifert H, Ackermann R, Burchardt M. Fibroblast Growth Factors and
their receptors in urological cancers: Basic research and clinical implications. Eur Urol
2003;261:1-11 (IF 5,634)
67. Schulz WA, Burchardt M, Grimm MO. Molecular diagnosis: how long until it is routine practice?
Urologe A 2003;42(5):623 (IF 0,404)
68. Descazeaud A, Rubin MA, Allory Y, Burchardt M, Salomon L, Chopin D, Abbou C, De La Taille
A. What information are urologists extracting from prostate needle biopsy reports and what do
they need for clinical management of prostate cancer? Eur Urol 2005;48(6):911-5 (IF 5,634)
69. Stolzenburg JU, Rabenalt R, Do M, Lee B, Truss MC, Schwaibold H, Burchardt M, Jonas U,
Liatsikos EN. Categorisation of complications of endoscopic extraperitoneal and laparoscopic
transperitoneal radical prostatectomy. World J Urol. 2006(1):88-93 (IF 2,7)
70. Stolzenburg JU, Rabenalt R, Do M, Lee B, Truss MC, McNeill A, Burchardt M, Jonas U,
Liatsikos EN. Complications of endoscopic extraperitoneal radical prostatectomy (EERPE):
prevention and management. World J Urol 2006;24(6):668-75 (IF 2,7)
71. Reuter CW, Morgan MA, Grunwald V, Herrmann TRW, Burchardt M, Ganser A. Targeting
Vascular Endothelial Growth Factor (VEGF)-Receptor-signaling in renal cell carcinoma. World J
Urol 2007;25(1):59-72 (IF 2,7)
72. Ramírez-Backhaus M, Rabenalt R, Jain S, Do M, Liatsikos E, Ganzer R, Horn LC, Burchardt M,
Jiménez-Cruz F, Stolzenburg JU. Value of frozen section biopsies during radical prostatectomy:
significance of the histological results. World J Urol. 2009. 27(2):227-34 (IF 2,7)
73. Stolzenburg JU, Kallidonis P, Till H, Burchardt M, Herrmann TR, Liatsikos EN. Current status of
laparoendoscopic single-site surgery in urology. World J Urol 2009 (IF 2,7)
4
Publikationen
Fallmitteilungen
74. De la Taille A, Hayek OR, Burchardt M, Burchardt T, Katz AE. Role of herbal compounds (PCSPES) in hormone-refractory prostate cancer: Two case reports. J Altern Complem Med 2000;
6(5):449-51 (IF 1,104)
Buchbeiträge/Fachzeitungen:
1.
2.
3.
4.
5.
6.
Burchardt M. Erektile Dysfunktion ist ein prognostischer Marker für kardiovaskuläre
Komplikationen der Hypertonie. In: DGU Kongressausgabe, 9/2002;S.13
Burchardt M. Erektile Dysfunktion und Hypertonie: Prognostischer Faktor. In: Diabetes News,
11/2002;1:11
Schulz WA, Burchardt M, Grimm MO. Molekulare Diagnostik: Wie lange ist der Weg in die
Praxis? Editorial in: Der Urologe 2003;5:623
Burchardt M. Zwei Drittel der Hypertoniker haben Erektionsprobleme. Dr. Schilke Medizinischer
Verlag GmbH 2002
Anastasiadis AG, Droggin D, Burchardt M, Shabsigh R. Physiology of erection and causes of
erectile dysfunction. In: Heart disease and erectile dysfunction. Edited by: Kloner RA, Humana
Press, Totowa, New Jersey, USA 2004
Burchardt M. Gleason score as a predictor of pathologic stage. EAU Congress News, March 22.
2007, p.23.
Sonstiges
Editorial
1. Burchardt M, Huland H. Treatment of localized prostate cancer. World J Urol
2007;25(1):1-2 (IF 2,7)
2. Burchardt M. Bon voyage and ship ahoy. World J Urol 2008;26(2):111-2 (IF 2.7)
3. Burchardt M, Stolzenburg JU. Complications in laparoscopic urology. World J Urol 2008
26(6):521-2 (IF 2,7)
4. Herrmann TR, Merseburger AS, Burchardt M. Considerations on prostate cancer: diagnosis
and treatment decisions. World J Urol. 2009. 27(5):579-80 (IF 2,7)
PUBLIZIERTE ABSTRACTA
rat and human penis. J Urol 1999;161(4):840
2. Burchardt T, Burchardt M, Chen MW, Shabsigh A, de la Taille A, Hayek O, Buttyan R.
J Urol 1999;161(4):208
3. Shabsigh A, Hayek O, Weiner D, Kaplan SA, Burchardt M, Buttyan R, Levin R. Partial bladder
outlet obstruction of the rat rapidly increases bladder blood flow. J Urol 1999;161(4):871
4. De la Taille, Cao Y, Buttyan R, McKiernan JM, Olsson CA, Burchardt M, Sawczuk IS, Katz AE.
Prostate Specific Membrane Antigen expression in renal tissues and in peripheral blood of kidney
cancer patients: A biomarker of vascular invasion. Urol 1999;161(4):730
5. Shabsigh A, Hayek O, Chen MW, Kaplan SA, Burchardt M, Burchardt T, Olsson CA, Buttyan R.
Early effects of castration on the vascular system of the rat ventral prostate gland. J Urol 1999;
161(4):872
6. Klein LT, Miller MI, Buttyan R, Raffo AJ, Burchardt M, Devries G, Cao YC, Olsson CA, Shabsigh
R. Apoptosis in the rat penis after penile denervation. J Urol 1996;155:A
5
Publikationen
7. Buttyan R, Shabsigh A, Burchardt M, Burchardt T, Chen MW. Androgenic effects on the prostatic
vascular system: Insights into the mechanism of prostate growth control. Eur Urol 1999;36(5):540
8. Burchardt T, Burchardt M, Shabsigh A, De la Taille A, Hayek O, Buttyan R. Transdifferentation of
LNCaP cells to a neuroendocrine cell phenotype under hormone depleted conditions. Eur Urol
1999; 36(5):497
9. Burchardt M, Burchardt T, Hayek O, Knight C, de la Taille A, Shabsigh A, Olsson CA, Buttyan R.
Vascular Endothelial Growth Factor expression is not affected by castration in the rat ventral
prostate. Eur Urol 1999;36(5):536
10. Burchardt M, Burchardt T, Chen MW, de la Taille A, Shabsigh A, Hayek O, Olsson CA, Buttyan
R. Phenotypic effects of modulated p53 expression in LNCaP cells using an inducible antisense
approach. Eur Urol 1999;36(5):527
11. De la Taille A, Hayek O, Buttyan R, Bagiella E, Burchardt M, Katz AE. In vitro and in vivo study
of a chinese herbal preparation PC-SPES in prostate cancer. Eur Urol 1999;36(5):514
12. De la Taille A, Buttyan R, Cao Yichen, Burchardt M, McKiernan J, Olsson CA, Sawczuk I, Katz
AE. Prostate Specific Membrane Antigen expression in renal tissues and in peripheral blood of
kidney cancer patients by nested RT-PCR: A biomarker of vascular invasion. Eur Urol
1999;36(5):498
13. De la Taille A, Katz AE, Buttyan R, Bagiella E, Burchardt M, Burchardt T, Olsson CA, Rubin M.
Microvessel density (MVD) using CD 34 is an independent predictor of PSA recurrence after
radical prostatectomy but CD 31 is not. Eur Urol 1999;36(5):536
14. De la Taille A, Chen MW, Burchardt T, Burchardt M, Shabsigh A, Hayek O, Buttyan R. Apoptotic
conversion: Prostate cancer cells can aquire novel genetic information by phagocytosis of
apoptotic antibodies. Eur Urol 1999;36(5):542
15. Shabsigh A, Hayek O, Burchardt T, Burchardt M, de la Taille A, Olsson CA, Buttyan R.
Vasodegeneration and vasoconstriction: Prominent early events associated with castrationinduced regression of the rat ventral prostate gland. Eur Urol 1999;36(5):538
16. Hayek O, Shabsigh A, Weiner D, Saidi J, Kaplan S, de la Taille A, Burchardt M, Buttyan R, Levin
R. Rapid increase in blood perfusion to the rat bladder after partial bladder outlet obstruction. Eur
Urol 1999;36(5):537
17. Shabsigh A, Burchardt T, Burchardt M, Hayek O, Shabsigh R, Buttyan R. The microvascular
anatomy of the mature rat ventral prostate gland. Eur Urol 1999;36(5):517
Vascular Endothelial Growth Factor (VEGF) in the adult rat and human penis. Int J Impot Res
1999;11(1):68
19. Burchardt T, Burchardt M, Baer L, Shabsigh A, Hayek O, de la Taille A, Shabsigh R. Erectile
dysfunction (ED) is a prognostic factor for cardiovascular complications of hypertension. Int J
Impot Res 1999;11(1):73
20. Burchardt M, Burchardt T, Kiss AJ, Baer L, Pawar RV, Karden J, de la Taille A, Shabsigh A,
Hayek O, Shabsigh R. Sexual dysfunction in patients with hypertension. New perspectives in the
managment of female sexual dysfunction, Jahrestreffen der Society for the Study of Impotence,
Boston, MA, USA, 1999
21. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A, de la Taille A, Hayek O,
Shabsigh R. Sexual dysfunction in female patients with hypertension. J Urol 2000;163(4):1068
22. Burchardt M, Burchardt T, Chen MW, Hayek O, Knight C, Shabsigh A, de la Taille A, Buttyan R.
Early effects of castration on Vascular Endothelial Growth Factor expression in the rat ventral
prostate. J Urol 2000;163(4):454
23. De la Taille A, Buttyan R, Hayek O, Bagiella E, Golliday E, Shabsigh A, Burchardt T, Burchardt
M, Katz AE. Experimental and clinical PC-SPES activity in prostate cancer. J Urol
2000;163(4):702
24. Shabsigh A, Badger C, Burchardt M, de la Taille A, Olsson CA, Buttyan R. The vascular
anatomy of the ventral prostate gland of the rat and the effects of castration on the micro-vascular
architecture of the prostate. J Urol 2000;163(4):931
25. Shabsigh A, Burchardt M, Burchardt T, Hayek O, Ghafar MA, Olsson CA, Buttyan R. Castration
induces hypoxia of the rat prostate epithelial cells. J Urol 2000;163(4);941
26. Ghafar MA, Kaplan SA, Shabsigh A, Burchardt M, Burchardt T, Buttyan R. In vivo activation of
the c-jun n-terminal kinase signaling pathway during castration–induced apoptosis of the rat
prostate epithelial cells. J Urol 2000;163(4):944
6
Publikationen
27. Burchardt M, Burchardt T, Shabsigh A, de la Taille A, Hayek O, Buttyan R. Transdifferentation of
LNCaP cells to a neuroendocrine cell phenotype in vivo and in vitro. Freundschaftstreffen
Deutsch-Französischer Urologen 2000, Nantes
28. Burchardt M, Burchardt T, de la Taille A, Buttyan R, Mazeman E, Ackermann R, Shabsigh R.
rat and human penis. BJU International 2000;86,Suppl.3:184
29. Burchardt M, Burchardt T, de la Taille A, Shabsigh A, Mazeman E, Ackermann R, Buttyan R.
Transdifferentation of prostate cancer cells to a neuroendocrine cell phenotype In Vitro and In
Vivo. BJU International 2000;86,Suppl.3:62
30. Burchardt M, Burchardt T, Buttyan R, Pulte T, Anastasiadis A, Olsson C, Shabsigh R. Expression
von VEGF mRNA Splicevarianten im Penisgewebe von Ratten und Menschen. Urologe A
2000;39:117
31. Burchardt M, Burchardt T, Olsson C, Buttyan R. Transdifferenzierung von
Prostatacarcinomzellen in einem neuroendokrinen Zellphänotyp in vitro und in vivo. Urologe A
2000;39:31
32. Burchardt M, Burchardt T, Chen MW, Shabsigh A, de la Taille A, Hayek O, Buttyan R.
Eur Urol 2000;38:531
33. Pulte T, Santourlidis S, Meyer A, Burchardt M, Ackermann R, Schulz W. Initial experience using
GSTP1 gene hypermethylation as a carcinoma marker in prostate biopsies. Eur Urol 2000;38:498
34. Burchardt M, Burchardt T, Buttyan R, Anastasiadis A, de la Taille A, Shabsigh A, Frank J,
Shabsigh R. Application for therapy of erectile dysfunction with angiogenic factors: Protein and
DNA transfer of VEGF 165 in the rat penis. Int J Impot Res 2000;12(3):62
35. Fleming MP, Davis AR, Burchardt T, Burchardt M, Shabsigh R, Baer L. Sexual functioning and
depression among women and men attending a hypertension clinic. Female Sexual Function
Forum New perspectives in the management of female sexual dysfunction. Oct 26-29, 2000,
Boston, MA, USA, Poster 3, page 60
36. Burchardt M, Burchardt T, Buttyan R, Shabsigh A, de la Taille A, Anastasiadis AG, Ghafar M,
Shabsigh R. Reduction of endothelial and smooth muscle density in the corpora cavernosa of the
diabetic rat. J Urol 2001;165(5):229
37. Ghafar MA, Anastasiadis AG, McKiernan J, Benson MC, Burchardt M, Chen MW, Buttyan R.
Simple androgen-deprivation induces a hypoxia-response in LNCAP prostate cancer cells. 4th
World Congress in Urologic Research, Society for Basic Urologic Research/European Society of
Urologic Research Symposium, Nov 29-Dec 2, 2001, Tucson, AZ, USA
38. Anastasiadis AG, Ghafar MA, Vacherot F, Benedit P, Chen MW, Shabsigh A, Burchardt M,
Shabsigh R, Chopin D, Buttyan R. Human hormone refractory prostate cancer cells can harbor
mutations in the 02-dependent degradation domain of Hypoxia inducible factor-1 (Hif-1 ). 4th
World Congress in Urologic Research, Society for Basic Urologic Research/European Society of
Urologic Research Symposium, Nov 29-Dec 2, 2001, Tucson, AZ, USA. Travel Award
39. Burchardt M, Burchardt T, Anastasiadis A, Ghafar M, de la Taille A, Shabsigh A, Cronauer M,
Buttyan R. Phenotypic effects of modulated p53 expression in LNCaP cells using an inducible
antisense approach. Nov 29-Dec 2, 2001, Tucson, AZ, USA. Travel Award
40. Anastasiadis AG, Davis AR, Fleming M, Cushman L, Barsbay D., Ghafar MA, Sawczuk IS,
Droggin D, Burchardt M, Shabsigh R. Sexual functioning among men and women with renal
cancer: Data from a national registry. Annual Female Sexual Function Forum (FSFF) meeting,
Oct. 25-28, 2001, Boston, MA, USA
41. Anastasiadis AG, Ghafar MA, Chen MW, Shabsigh A, Benedit P, Shabsigh R, Buttyan R,
Burchardt M, Vacherot F, Chopin D. Human hormone refractory prostate cancer cells harbor
mutations in the O2-dependent degradation domain of hypoxia inducible factor-1α (HIF-1α). AACR
2002;Proceedings of the AACR,Vol 43,37:8
42. Schulz WA, Elo JP, Florl AR, Burchardt M, Seifert HH, Visakorpi T. Genomweite DNAHypomethylierung korreliert in Prostatakarzinomen mit Veränderungen von Chromosom 8.
Experimentelle Urologie 2002, Hannover
43. Cronauer MV, Schulz WA, Burchardt M. Funktionelle Konsequenzen der Inaktivierung von p53
bei der Entwicklung des hormonrefraktären Prostatakarzinoms. Homburg 2002
44. Anastasiadis AG, Ghafar MA, Chen MW, Shabsigh A, Benedit P, Shabsigh R, Buttyan R,
Burchardt M, Vacherot F, Chopin D. Human hormone refractory prostate cancer cells harbor
7
Publikationen
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
mutations in the O2-dependent degradation domain of hypoxia inducible factor-1α (HIF-1α). J Urol
2002;167(4):202
Schulz WA, Elo JP, Florl AR, Pennanen S, Burchardt M, Ackermann A, Visakorpi T. Genomewide DNA hypomethylation correlates with alterations on chromosome 8 in prostate carcinoma. J
Urol 2002; 167(4):555
Burchardt M, Burchardt T, Shabsigh R. Erectile dysfunction is a prognostic factor for
cardiovascular complications of hypertension. BJU International 2002;90(Suppl.2):39
Burchardt M, Burchardt T, Anastasiadis A, Ghafar M, de la Taille A, Shabsigh A, Cronauer M,
Buttyan R. Phenotypic effects of modulated p53 expression in LNCaP cells using an inducible
antisense approach. BJU International 2002;90(Suppl.2):160
Burchardt M, Burchardt T, Cronauer M, Buttyan R. Phenotypische Auswirkungen durch
induzierbare Antisense veränderte p53 Expression in LNCaP-Zellen. Urologe (A) 2002;Suppl 1:8
Burchardt M, Burchardt T, Shabsigh R. Erektile Dysfunktion ist ein prognostischer Marker für
cardiovasculäre Komplikationen der Hypertension. Urologe (A) 2002;Suppl 1:65
Schulz WA, Elo JP, Florl AR, Burchardt M, Seifert HH, Visakorpi T. Genomweite DNAHypomethylierung korreliert in Prostatakarzinomen mit Veränderungen von Chromosome 8.
Urologe (A) 2002;Suppl 1:5
Anastasiadis AG, Stisser BC, Bemis DL, Salomon L, Ghafar MA, Burchardt M, Buttyan R. Cobalt
mimics hypoxia in its effects on cultured human prostate cancer cells. SBUR Fall Meeting,
Tucson, AZ, USA, Dez. 5-8, 2002
Quires L, Rubin M, Vacherot F, Chen MW, Gil Diez S, Salomon L, Burchardt M, Abbou C,
Buttyan R, Chopin D, de la Taille A. Beta-catenin switch in apoptosis-resistant and hormonerefractory prostate cancer cells. J Urol 2003;169(4):215
Burchardt M, Burchardt T, Buttyan R, Anastasiadis A, de la Taille A, Shabsigh A, Shabsigh R.
Angiogenic factors for therapy of ED: Protein and DNA transfer of VEGF in the rat penis. J Urol
2003;169(4):309
Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function
diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Urologe A
2003;42(Suppl.1):16
Burchardt M, Engers R, Mueller M, Burchardt T, Ackermann R, Gabbert HE, Epstein J I, Rubin
MA. Trends in Gleason Grading in Germany: Evaluation using prostate cancer tissue microarrays.
United States and Canadian Academy of Pathology Annual Meeting 2004
Burchardt M, Engers R, Mueller M, Burchardt T, Ackermann R, Gabbert HE, Epstein J I, Rubin
J Urol 2004; 171(4):224
Burchardt M, Mueller M, Engers R, Burchardt T, Ackermann R, Gabbert HE, Epstein J I, Rubin
Urologe (A) 2004;Suppl 1:42
Herrmann TRW, von Klot C, Burchardt M, Galanski M, Jonas U. Untypischer Flankenschmerz im
urologischen Nachtdienst – Die Spitze des Eisberges. 48. Jahrestagung des Norddeutschen
Urologenverbandes 2006, Berlin
Herrmann TRW, Bach T, Cellarius C, Teichmann HO, Burchardt M, Jonas U, Gross AJ. Bladder
neck incision in outpatient setting. A feasable procedure using Revolix 2 Micron CW-Laser. J
Endourol 2006; Suppl 20
Von Klot C, Herrmann TRW, Burchardt M, Galanski M, Jonas U. Urologische Folge einer
Sparringsverletzung. Ein Fallbericht. 48. Jahrestagung des Norddeutschen Urologenverbandes
2006, Berlin
Herrmann TRW, v Klot C, Imkamp F, Waldkirch E, Truss M, Stolzenburg U, Rabenalt R, Minh D,
Jonas U, Burchardt M. Endoskopische extraperitoneale radikale Prostatektomie – onkologische
und funktionelle Ergebnisse nach 250 konsekutiven Patienten. 49. Jahrestagung des
Norddeutschen Urologenverbandes, 1. Nordkongress 2007 Hannover. 3.-5.Mai 2007
Herrmann TRW, von Klot C, Ehlers St, Kreipe KH, Galanski M, Jonas U, Reinhard D, Burchardt
M. Alveoläres Rhabdomyosarkom der Prostata – Ein Fallbericht. 49. Jahrestagung des
Norddeutschen Urologenverbandes, 1. Nordkongress 2007 Hannover. 3.-5.Mai 2007
Von Klot C, Herrmann TRW, Kreipe KH, Galanski M, Jonas U, Burchardt M. Seminom des linken
Hodens und eine unklare Raumforderung der rechten Niere – Ein Fallbericht. 49. Jahrestagung
des Norddeutschen Urologenverbandes, 1. Nordkongress 2007 Hannover. 3.-5.Mai 2007
8
Publikationen
64. Endoscopic extraperitoneal radical prostatectomy – oncological and functional results of the first
250 consecutive patients. Herrmann TRW, von Klot C, Imkamp F, Truss MC, Waldkirch E,
Stolzenburg JU, Rabenalt R, Minh D, Jonas U, Burchardt M. Eur Urol 2007; Suppl 6(2):126
65. Burchardt M. How reliable is uropathologic grading? 22nd Annual Congress of the EAU, Berlin
March 24. 2007, State-of-the-art lecture, Sub-plennary session
66. Burchardt M, Cronauer M, Montenarh M, Jonas U, Prowald A. Down-regulation of ß-cateninmediated T-cell factor-signaling in prostate cancer cell lines by p53. Eur Urol 2007; Suppl 6(2):128
67. Imkamp F, Herrmann TRW, Jonas U, Rassweiler J, Stolzenburg J, Rabenalt R, Sulser T,
Burchardt M. Laparoscopy in Urology: Changing acceptance among urologists. Congress of the
DGU, Berlin September 26.-29. 2007
68. Imkamp F, Herrmann TRW, Al-Jundi M, Jonas U, Burchardt M. Single center long term results of
internal urethrotomy in 924 male patients. Annual meeting of the American Urological Association
17.-22.5.2008.
69. Herrmann TRW, Imkamp F, Kaaz AT, Koertner S, Witt M, John H, Bach T, Gross AJ, Rabenalt R,
Stolzenburg JU, Jonas U, Burchardt M. Initial experience in 32 robotic assisted radical
prostatectomy cases in a laparoscopy center. 50. Jahrestagung der Vereinigung Norddeutscher
Urologen 2008
9

Publikationen Prof. Dr. med. Martin Burchardt

Transcription

Similar documents

Gichtlgasse 3 - Caritas Krankenhaus St. Josef

Prof. Dr. med. Lukas Prantl Curriculum vitae

Fragen zur Sexualität bei TM (07/2000)

als pdf-Datei herunterladen

Techniker Krankenkasse

Die Deutsche Sportmedizin im Jahr 2007